Express Scripts’ Cost Cap For PCSK9s Applicable To Other Drugs, PBM Says

12 Oct 2015

If PCSK9 spending by Express Scripts clients surpasses the $750m limit set for 2016, the PBM will pick up the excess cost, under a novel drug management arrangement for Repatha and Praluent.

Pharmacy benefit manager Express Scripts Holding Co.’s commitment that its payer clients will spend no more than $750m collectively on the two new PCSK9 drugs is part of a new drug management approach that also could be applied to other drug classes, according to the firm.

“The cap we are offering each individual client is a novel approach to prescription drug management that we believe will...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Podium Policy Returns To US FDA, Or Is It Podcast Policy?

20 Jun 2025

• By Michael McCaughan

US FDA critics have long decried the practice of using informal communications to convey regulatory expectations as podium policy. In the Makary era, the phrase may need to be updated because the agency now seems to be specializing in policy by podcast.

US FDA’s Elsa AI Platform Is Not Guiding Regulatory Decisions, Official Says

20 Jun 2025

• By Cathy Kelly

Tala Fakhouri said the agency’s use of the AI tool in the review process has generated lots of questions.

Branch Chief Vijay Kumar Named Acting Head Of US FDA’s Cell, Gene Therapy Office

20 Jun 2025

• By Derrick Gingery

Kumar takes over as acting director of the Center for Biologics Evaluation and Research’s Office of Therapeutic Products days after director Nicole Verdun was ousted.